ClinVar Miner

Submissions for variant NM_000038.6(APC):c.6553A>G (p.Ser2185Gly)

dbSNP: rs1060503292
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV003766567 SCV000552556 uncertain significance Familial adenomatous polyposis 1 2023-07-08 criteria provided, single submitter clinical testing This sequence change replaces serine, which is neutral and polar, with glycine, which is neutral and non-polar, at codon 2185 of the APC protein (p.Ser2185Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with gallbladder and pancreatic cancer (PMID: 30093976). ClinVar contains an entry for this variant (Variation ID: 411410). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt APC protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002365659 SCV002663470 uncertain significance Hereditary cancer-predisposing syndrome 2019-12-03 criteria provided, single submitter clinical testing The p.S2185G variant (also known as c.6553A>G), located in coding exon 15 of the APC gene, results from an A to G substitution at nucleotide position 6553. The serine at codon 2185 is replaced by glycine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. This alteration was reported in a cohort of Asian patients with multiple primary cancer diagnoses undergoing multigene panel testing for hereditary cancer susceptibility (Chan GHJ et al. Oncotarget. 2018 Jul;9:30649-30660). In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
3DMed Clinical Laboratory Inc RCV000677772 SCV000803928 uncertain significance Malignant tumor of ascending colon 2017-12-14 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.